MeSH term
Frequency | Condition_Probility | Adult | 43 | 0.0 |
Comparative Study | 38 | 0.0 |
Humans | 242 | 0.0 |
Animals | 201 | 0.0 |
Base Sequence | 15 | 0.0 |
Molecular Sequence Data | 18 | 0.0 |
Organ Specificity | 3 | 0.0 |
Substrate Specificity | 11 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Cytochrome P-450 Enzyme System/metabolism | 8 | 3.0 |
Diterpenes/*pharmacology | 2 | 6.0 |
Dose-Response Relationship, Drug | 26 | 0.0 |
Glutathione Transferase/metabolism | 7 | 0.0 |
Imidazoles/*toxicity | 46 | 100.0 |
Micronucleus Tests | 5 | 10.0 |
Mutagens/*toxicity | 32 | 31.0 |
Research Support, Non-U.S. Gov't | 177 | 0.0 |
Child | 7 | 0.0 |
Female | 87 | 0.0 |
Poultry | 2 | 12.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Biotransformation | 51 | 9.0 |
Cell Line | 24 | 0.0 |
DNA Damage | 9 | 1.0 |
Mutagens/metabolism/*toxicity | 2 | 50.0 |
Smoke/*adverse effects | 2 | 10.0 |
*Tobacco | 2 | 8.0 |
Rats | 109 | 0.0 |
Rats, Inbred F344 | 45 | 11.0 |
Rats, Sprague-Dawley | 19 | 0.0 |
Amines/*analysis | 10 | 100.0 |
Chickens | 4 | 0.0 |
Chromatography, High Pressure Liquid | 26 | 1.0 |
Cookery/*methods | 3 | 75.0 |
Heterocyclic Compounds/*analysis | 9 | 100.0 |
Meat/adverse effects/*analysis | 3 | 100.0 |
Mutagens/*analysis | 7 | 41.0 |
Temperature | 3 | 0.0 |
Environmental Exposure | 5 | 3.0 |
Food Analysis | 7 | 46.0 |
Meat/*analysis | 10 | 76.0 |
Time Factors | 8 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 6 | 6.0 |
Cells, Cultured | 23 | 0.0 |
Disease Models, Animal | 7 | 0.0 |
Imidazoles/metabolism/toxicity | 3 | 100.0 |
Carcinogens/*metabolism/pharmacokinetics | 2 | 100.0 |
Hair/chemistry/*metabolism | 2 | 66.0 |
Heterocyclic Compounds | 2 | 50.0 |
Imidazoles/*metabolism/pharmacokinetics | 2 | 50.0 |
Mice | 46 | 0.0 |
Quinoxalines/*metabolism/pharmacokinetics | 2 | 100.0 |
Male | 128 | 0.0 |
Rats, Wistar | 7 | 0.0 |
Amines/*pharmacokinetics | 2 | 50.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 3 | 20.0 |
Imidazoles/metabolism | 5 | 38.0 |
Immunoblotting | 3 | 0.0 |
Isoenzymes/genetics/metabolism | 4 | 2.0 |
Mutagenicity Tests | 36 | 22.0 |
Quinolines/metabolism | 6 | 54.0 |
Sulfotransferases/genetics/*metabolism | 2 | 25.0 |
Arylamine N-Acetyltransferase/*metabolism | 5 | 15.0 |
Cytochrome P-450 CYP1A2/*metabolism | 7 | 9.0 |
Imidazoles/*urine | 8 | 100.0 |
Mass Fragmentography | 6 | 2.0 |
Phenotype | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 105 | 0.0 |
Animals, Genetically Modified | 7 | 2.0 |
Cell Transformation, Neoplastic/drug effects | 2 | 5.0 |
Glutathione/metabolism | 2 | 0.0 |
Liver/metabolism | 4 | 0.0 |
Mutagenesis | 5 | 0.0 |
Mutagenicity Tests/methods | 3 | 25.0 |
Carcinogenicity Tests | 5 | 6.0 |
Carcinogens/*analysis | 8 | 61.0 |
DNA Adducts/*analysis | 8 | 18.0 |
Imidazoles/analysis | 5 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 41 | 0.0 |
Carcinogens/metabolism/*toxicity | 3 | 30.0 |
Diet | 20 | 5.0 |
Breast Neoplasms/*etiology | 4 | 20.0 |
Carcinogens/*adverse effects | 4 | 18.0 |
Smoking/*adverse effects | 3 | 1.0 |
Amines/adverse effects/analysis | 2 | 66.0 |
Breast Neoplasms/*chemically induced | 2 | 66.0 |
Cookery | 33 | 61.0 |
Glucuronides/urine | 4 | 100.0 |
Heterocyclic Compounds/adverse effects/analysis | 2 | 66.0 |
Imidazoles/*adverse effects | 3 | 60.0 |
Meat/analysis | 6 | 75.0 |
Comet Assay | 7 | 10.0 |
Heterocyclic Compounds/*pharmacology | 3 | 20.0 |
Mutagenesis/drug effects | 2 | 28.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Amines/metabolism | 2 | 15.0 |
Chromatography, High Pressure Liquid/methods | 4 | 2.0 |
Food Contamination/*analysis | 2 | 13.0 |
Lactobacillus/*metabolism | 2 | 66.0 |
Metabolic Detoxication, Drug | 6 | 7.0 |
Mutagens/*metabolism | 14 | 37.0 |
*Base Pair Mismatch | 4 | 4.0 |
Carcinogens/*toxicity | 34 | 30.0 |
Mutation | 17 | 0.0 |
Anticarcinogenic Agents/pharmacology | 2 | 7.0 |
Antimutagenic Agents/*pharmacology | 8 | 53.0 |
Bacterial Proteins/genetics | 2 | 2.0 |
Colon/*drug effects | 2 | 40.0 |
*Escherichia coli Proteins | 6 | 2.0 |
Frameshift Mutation | 3 | 0.0 |
Mutagens/pharmacology | 2 | 5.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Weight Gain/drug effects | 2 | 9.0 |
DNA Mutational Analysis | 7 | 0.0 |
Drug Synergism | 3 | 0.0 |
Imidazoles/*pharmacology | 7 | 9.0 |
Mutation/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
*Trans-Activators | 3 | 0.0 |
Biotransformation/drug effects | 2 | 6.0 |
Cytochrome P-450 CYP1A2/metabolism | 8 | 8.0 |
Hepatocytes/drug effects/*metabolism | 2 | 13.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Species Specificity | 17 | 0.0 |
Spectrometry, Mass, Electrospray Ionization | 3 | 3.0 |
Theophylline/*analogs & derivatives/pharmacology | 2 | 18.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Adolescent | 11 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 3 | 17.0 |
Quinolines/*pharmacokinetics | 2 | 20.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Chromatography, Liquid | 6 | 5.0 |
Diet, Vegetarian | 2 | 18.0 |
*Meat | 14 | 33.0 |
Risk Factors | 14 | 0.0 |
Spectrum Analysis, Mass | 15 | 2.0 |
Aflatoxin B1/toxicity | 2 | 22.0 |
Imidazoles/toxicity | 8 | 100.0 |
Sex Characteristics | 5 | 0.0 |
Cocarcinogenesis | 2 | 7.0 |
Colonic Neoplasms/*chemically induced/*genetics | 2 | 100.0 |
*DNA Repair | 6 | 0.0 |
Imidazoles | 4 | 33.0 |
Mice, Knockout | 4 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
*Mutagenesis | 5 | 8.0 |
Mutagens | 3 | 9.0 |
Carcinogens/*metabolism | 25 | 32.0 |
Cattle | 17 | 0.0 |
Eating | 2 | 1.0 |
Hydrolysis | 4 | 0.0 |
Kinetics | 7 | 0.0 |
Middle Aged | 33 | 0.0 |
Aged | 24 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Carcinogens/metabolism | 2 | 6.0 |
Case-Control Studies | 4 | 0.0 |
DNA/metabolism | 4 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Food | 12 | 10.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Imidazoles/metabolism/*pharmacokinetics | 3 | 60.0 |
Mutagens/metabolism | 4 | 14.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Biological Markers/blood | 2 | 0.0 |
Meat | 13 | 39.0 |
Amines/*toxicity | 6 | 54.0 |
Cell Transformation, Neoplastic/*chemically induced | 2 | 25.0 |
*Cookery | 12 | 70.0 |
Heterocyclic Compounds/*toxicity | 6 | 60.0 |
Mice, Inbred C57BL | 12 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Heat | 20 | 3.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Amines/*administration & dosage | 3 | 100.0 |
Child, Preschool | 6 | 0.0 |
Food Contamination | 5 | 16.0 |
Heterocyclic Compounds/*administration & dosage | 3 | 100.0 |
Infant | 2 | 0.0 |
Nutrition Surveys | 2 | 9.0 |
COS Cells | 4 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Transfection | 5 | 0.0 |
Antioxidants/pharmacology | 3 | 1.0 |
Benzo(a)pyrene/pharmacology | 2 | 9.0 |
*Carcinogens | 8 | 25.0 |
Cytochrome P-450 CYP1A1/metabolism | 3 | 4.0 |
Cytochrome P-450 Enzyme System/*metabolism | 9 | 1.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Imidazoles/pharmacology | 6 | 2.0 |
Mixed Function Oxygenases/metabolism | 2 | 1.0 |
Protein Binding | 3 | 0.0 |
Carcinogens, Environmental/*toxicity | 3 | 20.0 |
Lymphocytes | 2 | 1.0 |
Carcinogens/*pharmacokinetics | 8 | 34.0 |
Glucuronosyltransferase/*metabolism | 2 | 3.0 |
Imidazoles/*pharmacokinetics | 8 | 57.0 |
Microsomes/enzymology | 3 | 2.0 |
*Food Contamination | 4 | 20.0 |
Neoplasms/chemically induced | 4 | 33.0 |
Reproducibility of Results | 8 | 0.0 |
Risk Assessment | 5 | 0.0 |
Catalysis | 5 | 0.0 |
Cytochrome P-450 CYP1A2/genetics/*metabolism | 2 | 8.0 |
Gene Expression Regulation, Enzymologic/drug effects | 2 | 1.0 |
Hydroxylation | 7 | 1.0 |
Imidazoles/*pharmacokinetics/*toxicity | 2 | 100.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Reference Standards | 2 | 0.0 |
Sensitivity and Specificity | 9 | 0.0 |
Spectrum Analysis, Mass/*methods | 2 | 5.0 |
Amines/*adverse effects | 2 | 100.0 |
Diet/adverse effects | 5 | 35.0 |
Heterocyclic Compounds/*adverse effects | 2 | 100.0 |
Meat/*adverse effects | 2 | 40.0 |
Reference Values | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
*Genes, APC | 4 | 4.0 |
Intestinal Neoplasms/chemically induced/*genetics | 2 | 100.0 |
Administration, Oral | 8 | 0.0 |
Biological Availability | 8 | 2.0 |
Biological Transport | 5 | 0.0 |
Dogs | 6 | 0.0 |
Tissue Distribution | 12 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cytosol/metabolism | 3 | 0.0 |
DNA/drug effects/metabolism | 2 | 4.0 |
DNA Adducts/*biosynthesis | 3 | 37.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Base Pair Mismatch | 3 | 1.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Gene Deletion | 4 | 0.0 |
Genes, APC/*genetics | 3 | 10.0 |
*Mutation | 4 | 0.0 |
Acetylation | 7 | 1.0 |
Animals, Congenic | 3 | 17.0 |
Arylamine N-Acetyltransferase/genetics | 2 | 3.0 |
Carcinogens/administration & dosage/*toxicity | 2 | 100.0 |
Hamsters | 21 | 0.0 |
Mammary Neoplasms, Experimental/*chemically induced/genetics/pathology | 2 | 100.0 |
Mesocricetus | 5 | 3.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Arylamine N-Acetyltransferase/*genetics | 2 | 0.0 |
DNA/drug effects | 4 | 18.0 |
Imidazoles/metabolism/*toxicity | 5 | 100.0 |
Polymorphism, Genetic | 5 | 0.0 |
Mammary Neoplasms, Experimental/*chemically induced | 2 | 50.0 |
Quinolines/toxicity | 6 | 75.0 |
Carbon Radioisotopes | 4 | 4.0 |
Spectrum Analysis, Mass/methods | 2 | 5.0 |
Plasmids | 4 | 0.0 |
Pyridines/urine | 2 | 100.0 |
Carcinogens/toxicity | 3 | 5.0 |
*Cocarcinogenesis | 2 | 9.0 |
Colonic Neoplasms/*genetics | 2 | 2.0 |
DNA Repair/*physiology | 2 | 1.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 3 | 3.0 |
Imidazoles/*analysis | 3 | 100.0 |
Microsomes, Liver/metabolism | 7 | 4.0 |
Amino Acid Sequence | 6 | 0.0 |
Cytoskeletal Proteins/*genetics | 2 | 1.0 |
*Aryl Hydrocarbon Hydroxylases | 4 | 0.0 |
Gene Expression | 4 | 0.0 |
Organ Culture Techniques | 3 | 0.0 |
*Diet | 11 | 5.0 |
Quinoxalines/analysis | 2 | 100.0 |
Smoking | 3 | 0.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Colon/metabolism | 5 | 4.0 |
Cytosol/enzymology | 3 | 1.0 |
DNA Adducts/metabolism | 10 | 28.0 |
Liver/enzymology | 5 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/metabolism | 2 | 7.0 |
*DNA Damage | 10 | 1.0 |
Genotype | 7 | 0.0 |
Quinoxalines/*toxicity | 7 | 100.0 |
Carcinogens/*pharmacology | 4 | 6.0 |
Immunohistochemistry | 2 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
CHO Cells | 3 | 0.0 |
Isoenzymes/*metabolism | 3 | 1.0 |
Mutagens/toxicity | 10 | 27.0 |
Sequence Deletion | 2 | 0.0 |
DNA Adducts | 5 | 7.0 |
*Food | 9 | 10.0 |
Carcinogens/pharmacokinetics | 2 | 13.0 |
Dietary Supplements | 2 | 2.0 |
*Flavones | 2 | 28.0 |
Imidazoles/pharmacokinetics | 3 | 75.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Amines/*pharmacology | 2 | 33.0 |
Cell Survival/drug effects | 6 | 0.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 2 | 15.0 |
DNA Adducts/*metabolism | 3 | 6.0 |
Carcinogens/metabolism/*pharmacology | 2 | 28.0 |
*Heat | 5 | 4.0 |
Salmonella typhimurium/genetics | 5 | 35.0 |
Signal Transduction | 2 | 0.0 |
Arylamine N-Acetyltransferase/metabolism | 3 | 14.0 |
Carbolines/toxicity | 5 | 71.0 |
Quinoxalines/toxicity | 2 | 40.0 |
Caco-2 Cells | 2 | 0.0 |
Mutagens/*pharmacokinetics | 5 | 62.0 |
Amines/toxicity | 2 | 50.0 |
DNA Repair/*drug effects | 3 | 9.0 |
In Vitro | 11 | 0.0 |
Models, Biological | 3 | 0.0 |
Imidazoles/*metabolism | 26 | 83.0 |
Microsomes, Liver/*metabolism | 9 | 5.0 |
Quinolines/*metabolism | 5 | 29.0 |
Carcinogens/administration & dosage/*metabolism | 3 | 100.0 |
Imidazoles/administration & dosage/*metabolism | 4 | 100.0 |
Quinoxalines/administration & dosage/*metabolism | 2 | 100.0 |
Cytochrome P-450 CYP1A2/genetics | 2 | 18.0 |
Serum Albumin/metabolism | 2 | 1.0 |
DNA/*metabolism | 3 | 0.0 |
Epithelial Cells/metabolism | 3 | 0.0 |
Quinoxalines/*metabolism | 6 | 66.0 |
Hemoglobins/analysis | 2 | 0.0 |
Meat/adverse effects | 3 | 37.0 |
Autoradiography | 2 | 0.0 |
Carcinogens/metabolism/pharmacology | 2 | 66.0 |
DNA Adducts/*chemistry | 2 | 33.0 |
Phosphorus Radioisotopes | 5 | 8.0 |
Glucuronates/*metabolism | 4 | 19.0 |
Microsomes/*enzymology | 2 | 4.0 |
Questionnaires | 3 | 0.0 |
DNA Adducts/*antagonists & inhibitors | 2 | 100.0 |
English Abstract | 6 | 0.0 |
*Flavonoids | 2 | 8.0 |
Phenols/*pharmacology | 2 | 5.0 |
Plant Extracts/pharmacology | 2 | 5.0 |
Polymers/*pharmacology | 2 | 12.0 |
*Tea | 4 | 19.0 |
Aminobiphenyl Compounds/*metabolism | 3 | 50.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Microsomes, Liver/enzymology | 3 | 1.0 |
Molecular Structure | 5 | 0.0 |
Salmonella typhimurium/drug effects/genetics | 5 | 35.0 |
Structure-Activity Relationship | 5 | 0.0 |
Amines/*metabolism | 4 | 22.0 |
Biological Markers | 5 | 0.0 |
Cytochrome P-450 Enzyme System/*analysis | 2 | 10.0 |
DNA Adducts/analysis/*metabolism | 3 | 100.0 |
Heterocyclic Compounds/*metabolism | 3 | 30.0 |
Carcinogens/pharmacokinetics/*toxicity | 2 | 40.0 |
*Food Analysis | 6 | 54.0 |
Imidazoles/pharmacokinetics/*toxicity | 3 | 100.0 |
Mutagens/pharmacokinetics/*toxicity | 3 | 50.0 |
Oxidation-Reduction | 9 | 0.0 |
*DNA Adducts | 3 | 8.0 |
Quinolines/*toxicity | 8 | 72.0 |
Flavonoids/*pharmacology | 3 | 3.0 |
Liver/*drug effects/metabolism | 3 | 6.0 |
Amines/adverse effects/*analysis | 2 | 100.0 |
Colonic Neoplasms/chemically induced | 5 | 71.0 |
Fishes | 6 | 7.0 |
Heterocyclic Compounds/adverse effects/*analysis | 2 | 100.0 |
Prostatic Neoplasms/chemically induced | 2 | 66.0 |
Prostate/chemistry | 2 | 10.0 |
Rabbits | 8 | 0.0 |
DNA, Complementary | 3 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
DNA Repair/*genetics | 2 | 0.0 |
Liver/drug effects | 2 | 5.0 |
Aflatoxin B1/pharmacology | 2 | 100.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
DNA/*biosynthesis | 2 | 2.0 |
Isoflavones/*pharmacology | 2 | 8.0 |
Macaca fascicularis | 9 | 3.0 |
Tea | 3 | 37.0 |
Urothelium/*metabolism | 2 | 25.0 |
Colonic Neoplasms/chemically induced/genetics/pathology | 2 | 100.0 |
Animals, Newborn | 3 | 0.0 |
Chlorophyllides/pharmacology | 2 | 66.0 |
Lactation | 2 | 3.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Meat/*adverse effects/analysis | 2 | 100.0 |
Prospective Studies | 4 | 0.0 |
United States | 2 | 0.0 |
Rats, Inbred ACI | 2 | 13.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
*Imidazoles | 5 | 62.0 |
*Mutagens | 7 | 21.0 |
Point Mutation | 3 | 0.0 |
*Quinolines | 2 | 50.0 |
Dietary Proteins/administration & dosage | 3 | 8.0 |
*Meat Products | 3 | 100.0 |
Liver/*enzymology | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Carcinogens/metabolism/*pharmacokinetics | 2 | 66.0 |
Spectrometry, Fluorescence | 6 | 1.0 |
Arylamine N-Acetyltransferase/genetics/*metabolism | 3 | 18.0 |
Quinoxalines/*urine | 3 | 75.0 |
Digestive System/*metabolism | 2 | 5.0 |
Salmonella typhimurium | 2 | 22.0 |
Colon | 2 | 7.0 |
Salmonella typhimurium/drug effects | 4 | 22.0 |
DNA Repair | 4 | 0.0 |
Genes, APC | 3 | 3.0 |
Genes, ras | 2 | 0.0 |
Heterozygote | 3 | 0.0 |
Mutagenesis/*drug effects | 2 | 66.0 |
Adenocarcinoma/chemically induced | 3 | 75.0 |
Neoplasms, Experimental/*chemically induced | 2 | 100.0 |
Risk | 2 | 0.0 |
Theophylline/analogs & derivatives/pharmacology | 2 | 9.0 |
Mice, Mutant Strains | 3 | 0.0 |
Mutagens/*pharmacology | 3 | 10.0 |
Quinolines/pharmacology | 3 | 13.0 |
Quinolines/metabolism/*toxicity | 2 | 100.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Food Handling | 3 | 23.0 |
Biological Markers/*urine | 2 | 16.0 |
Glucuronosyltransferase/metabolism | 2 | 7.0 |
Cricetulus | 3 | 0.0 |
DNA Adducts/analysis | 3 | 23.0 |
Acetyltransferases/*metabolism | 2 | 2.0 |
Imidazoles/*administration & dosage | 2 | 33.0 |
Plants, Toxic | 2 | 5.0 |
Urine/*chemistry | 2 | 25.0 |
Epithelium/drug effects/metabolism | 2 | 3.0 |
Binding Sites | 3 | 0.0 |
Protein Conformation | 2 | 0.0 |
Carbon Radioisotopes/diagnostic use | 2 | 3.0 |
Neoplasms/*chemically induced | 2 | 8.0 |
DNA, Satellite/genetics | 2 | 1.0 |
Adsorption | 2 | 1.0 |
Carcinogens/*isolation & purification | 3 | 100.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Algorithms | 2 | 0.0 |
*Chickens | 2 | 22.0 |
Spectrophotometry, Ultraviolet | 5 | 2.0 |
Cytochrome P-450 CYP1A2 | 7 | 8.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 2 | 1.0 |
Oxidoreductases/metabolism | 2 | 2.0 |
Age Factors | 2 | 0.0 |
Body Weight/drug effects | 2 | 1.0 |
Ultraviolet Rays | 2 | 0.0 |
Carcinogens/*metabolism/toxicity | 3 | 18.0 |
Mutagens/*metabolism/toxicity | 2 | 50.0 |
Quinoxalines/metabolism/toxicity | 2 | 66.0 |
Swine | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Microsomes, Liver/enzymology/*metabolism | 2 | 2.0 |
Mammary Neoplasms, Experimental/*chemically induced/pathology | 2 | 50.0 |
Rats, Inbred Strains | 3 | 0.0 |
Colonic Neoplasms/chemically induced/*genetics | 2 | 40.0 |
Dietary Fats | 2 | 5.0 |
Liver Neoplasms/chemically induced | 2 | 33.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Mutagens/*metabolism/pharmacokinetics | 2 | 100.0 |
Callithrix | 2 | 2.0 |
Microsomes, Liver/*enzymology | 5 | 2.0 |
Rodentia | 2 | 2.0 |
Maillard Reaction | 2 | 66.0 |
Amines/analysis/*toxicity | 2 | 100.0 |
Carcinogens/analysis/*toxicity | 2 | 66.0 |
Heterocyclic Compounds/analysis/*toxicity | 2 | 100.0 |
Mutagens/analysis/*toxicity | 2 | 66.0 |
Heterocyclic Compounds/metabolism | 2 | 40.0 |
Intestines/*microbiology | 2 | 12.0 |
Glutathione/*metabolism | 2 | 3.0 |
Heterocyclic Compounds/*adverse effects/analysis | 2 | 100.0 |
Amines/adverse effects | 2 | 40.0 |
Imidazoles/adverse effects | 2 | 50.0 |
Imidazoles/*metabolism/urine | 2 | 100.0 |
Carcinogens | 5 | 6.0 |
Food/*toxicity | 2 | 100.0 |
Cytochrome P-450 Enzyme System/*physiology | 2 | 3.0 |
Glucuronidase/metabolism | 2 | 6.0 |
Guinea Pigs | 2 | 0.0 |
Feces/chemistry | 2 | 4.0 |
Mutagens/analysis | 2 | 28.0 |
*Plants, Toxic | 2 | 5.0 |
Imidazoles/*pharmacokinetics/toxicity | 2 | 100.0 |
Polyethyleneimine | 2 | 33.0 |
SOS Response (Genetics) | 2 | 50.0 |
Imidazoles/*pharmacokinetics/urine | 2 | 100.0 |
alpha-Thalassemia/*genetics/metabolism/pathology | 2 | 100.0 |
beta-Thalassemia/*genetics/metabolism/pathology | 2 | 100.0 |
DNA/*drug effects | 2 | 11.0 |
Aroclors/pharmacology | 2 | 40.0 |
Pancreatic Neoplasms/chemically induced | 2 | 100.0 |
Food/*adverse effects | 2 | 100.0 |
Prostate/*drug effects | 2 | 50.0 |
Genes, Reporter | 2 | 0.0 |
